Differential expression of nucleotide pyrophosphatase/phosphodiesterases by Walker 256 mammary cancer cells in solid tumors and malignant ascites

Life Sciences

Volumn 86, Issue 11-12, 2010, Pages 435-440

  Buffon, Andréia ^a   Casali, Emerson A ^a,b   Cardoso, Valesca V ^b   Zerbini, Luiz F ^c   Robson, Simon C ^d   Sarkis, João J F ^a   Wink, Márcia R ^e  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b CENTRO UNIVERSITÁRIO METODISTA IPA   (Brazil)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Adenine nucleotides; Cancer; NPPs; Tumor growth; Walker 256 tumor

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AUTOTAXIN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES CELL; ASCITES TUMOR; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HYDROLYSIS; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; WALKER CARCINOMA;

ANIMALS; ASCITES; CARCINOMA 256, WALKER; CATIONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; KINETICS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NUCLEOSIDES; NUCLEOTIDES; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77949534422     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.01.015     Document Type: Article

References (40)

1. Agteresch H.J., Dagnelie P.C., van den Berg J.W., Wilson J.H. Adenosine triphosphate: established and potential clinical applications. Drugs 1999, 58(2):211-232.
2. Airas L., Hellman J., Salmi M., Bono P., Purune Smith D.J., Jalkanen S. CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. Journal of Experimental Medicine 1995, 182(5):1603-1608.
3. Bours M.J., Swennen E.L., Di Virgilio F., Cronstein B.N., Dagnelie P.C. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacology & Therapeutics 2006, 112(2):358-404.
4. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-bye binding. Analytical Biochemistry 1976, 72:248-254.
5. Buffon A., Ribeiro V.B., Wink M.R., Casali E.A., Sarkis J.J. Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: molecular identification, kinetic characterization and biochemical properties. Life Sciences 2007, 80(10):950-958.
6. Buffon A., Wink M.R., Ribeiro B.V., Casali E.A., Libermann T.A., Zerbini L.F., Robson S.C., Sarkis J.J. NTPDase and 5' ecto-nucleotidase expression profiles and the pattern of extracellular ATP metabolism in the Walker 256 tumor. Biochimica et Biophysica Acta 2007, 1770(8):1259-1265.
7. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacological Reviews 2006, 58(1):58-86.
8. Cavenagh J.D., Cahill M.R., Kelsey S.M. Adhesion molecules in clinical medicine. Critical Reviews in Clinical Laboratory Sciences 1998, 35(5):415-459.
9. Clark C.M., Goodlad G.A. Protein and enzyme content of plasma membranes derived from Walker 256 carcinoma cells grown as ascitic or solid tumours. Cancer Letters 1993, 68(2-3):91-94.
10. Dzhandzhugazyan K.N., Kirkin A.F., thor Straten P., Zeuthen J. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Letters 1998, 430(3):227-230.
11. Goding J.W., Grobben B., Slegers H. Physiological and pathophysiological functions of the ectonucleotide pyrophosphatase/phosphodiesterase family. Biochimica et Biophysica Acta 2003, 1638(1):1-19.
12. Guaitani A., Recchia M., Carli M., Rocchtti M., BartǑsek I., Garattini S. Walker carcinoma 256: a model for studies on tumor induced anorexia and cachexia. Oncology 1982, 39(3):173-178.
13. He Y.C., Wang Y.H., Cao J., Chen J.W., Pan D.Y., Zhou Y.K. Effect of complex amino acid imbalance on growth of tumor in tumor-bearing rats. World Journal of Gastroenterology 2003, 9(12):2772-2775.
14. Hosoda N., Hoshino S.I., Kanda Y., Katada T. Inhibition of phosphodiesterase/pyrophosphatase activity of PC-1 by its association with glycosaminoglycans. European Journal of Biochemistry 1999, 265(2):763-770.
15. Huang R., Rosenbach M., Vaughn R., Provvedini D., Rebbe N., Hickman S., Goding J., Terkeltaub R. Expression of the murine plasma cell nucleotide pyrophosphohydrolase PC-1 is shared by human liver, bone, and cartilage cells. Journal of Clinical Investigation 1994, 94(2):560-567.
16. Ikeda Y., Hayashi I., Kamoshita E., Yamazaki A., Endo H., Ishihara K., Yamashina S., Tsutsumi Y., Matsubara H., Majima M. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Research 2004, 64(15):5178-5185.
17. Kansas G.S., Wood G.S., Tedder T.F. Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. Journal of Immunology 1991, 146(7):2235-2244.
18. Kelly S.J., Dardinger D.E., Butler L.G. Hydrolysis of phopshonate esters catalyzed by 5'-nucleotide phosphodiesterase. Biochemistry 1975, 14(22):4983-4988.
19. Moolenaar W.H. Lysophospholipids in the limelight: autotaxin takes center stage. Journal of Cell Biology 2002, 158(2):197-199.
20. Nam S.W., Clair T., Campo C.K., Lee H.Y., Liotta L.A., Stracke M.L. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000, 19(2):241-247.
21. Nam S.W., Clair T., Kim Y.S., Mcmarlin A., Schiffmann E., Liotta L.A., Stracke M.L. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Research 2001, 61(18):6938-6944.
22. Piffar P.M., Fernandez R., Tchaikovski O., Hirabara S.M., Folador A., Pinto G.J., Jakobi S., Gobbo-Bordon D., Rohn T.V., Fabricio V.E., Moretto K.D., Tosta E., Curi R., Fernandes L.C. Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Letters 2003, 201(2):139-148.
23. Rettori O., Vieira-Matos N.A., Tahin Q.S. Variability and discontinuity of the pathognomonic systemic effects caused by the Walker 256 tumor progression in rats. Tumori 1995, 81(5):370-377.
24. Robson S., Sévigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationship and pathophysiological significance. Purinergic Signalling 2006, 2(2):409-430.
25. Sakura H., Nagashima S., Nakashima A., Maeda M. Characterization of fetal serum 5'-nucleotide phosphodiesterase: a novel function as a platelet aggregation inhibitor in fetal circulation. Thrombosis Research 1998, 91(2):83-89.
26. Spychala J. Tumor-promoting functions of adenosine. Pharmacology & Therapeutics 2000, 87(2-3):161-173.
27. Spychala J., Lazarowski E., Ostapkowicz A., Ayscue L.H., Jin A., Mitchell B.S. Role of estrogen in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. Clinical Cancer Research 2004, 10(2):708-717.
28. Stefan C., Stalmans W., Bollen M. Growth-related expression of the ectonucleotide pyrophosphatase PC-1 in rat liver. Hepatology 1998, 28(6):1497-1503.
29. Stefan C., Gijsbers R., Stalmans W., Bollen M. Differential regulation of the expression of nucleotide pyrophosphatases/phosphodiesterases in rat liver. Biochimica et Biophysica Acta 1999, 1450(1):45-52.
30. Stefan C., Jansen S., Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends in Biochemical Sciences 2005, 30(10):542-550.
31. Stefan C., Jansen S., Bollen M. Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signalling 2006, 2(2):361-370.
32. Stracke M.L., Krutzsch H.C., Unsworth E.J., Arestad A., Cioce V., Schiffmann E., Liotta L.A. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulation protein. Journal of Biological Chemistry 1992, 267(4):2524-2529.
33. Vollmayer P., Koch M., Braun N., Heine P., Servos J., Israr E., Kegel B., Zimmermann H. Multiple ecto-nucleotidase in PC12 cells: identification and cellular distribution after heterologous expression. Journal of Neurochemistry 2001, 78(5):1019-1028.
34. Vollmayer P, Clair T, Goding JW, Sano K, Servos J, Zimmermann H Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatase/phophodiesterases. European Journal of Biochemistry 2003, 270(14):2971-2978.
35. White N., Burnstock G. P2 receptors and cancer. Trends in Pharmacological Sciences 2006, 27(4):211-217.
36. Wink M.R., Lenz G., Braganhol E., Tamajusuku A.S., Schwartsmann G., Sarkis J.J., Battastini A.M.O. Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Letters 2003, 198(2):211-218.
37. Wink M.R., Braganhol E., Tamajusuku A.S., Lenz G., Zerbini L.F., Libermann T.A., Sévigny J., Battastini A.M.O., Robson S.C. Nucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39l1) is the dominant ectonucleotidase expressed by rat astrocytes. Neuroscience 2006, 138(2):421-432.
38. Yano Y., Hayashi Y., Sano K., Shinmaru H., Kuroda Y., Yokozaki H., Yoon S., Kasuga M. Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-3 (E-NPP3/CD203c/PD Ibeta/B10/gp 130RB13-6) in human colon carcinoma. International Journal of Molecular Medicine 2003, 12(5):763-766.
39. Yano Y., Hayashi Y., Sano K., Nagano H., Nakaji M., Seo Y., Ninomiya T., Yoon S., Yokozaki H., Kasuga M. Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases. Cancer Letters 2004, 207(2):139-147.
40. Zerbini L.F., Wang Y., Cho J.Y., Libermann T.A. Constitutive activation of nuclear factor kB p50/p65 and Fra-1 and junD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Research 2003, 63(9):2206-2215.